Loading...

Tom De Potter - First-in-human results of ultra-low-temperature continuous ablation

388 views

Loading...

Loading...

Transcript

The interactive transcript could not be loaded.

Loading...

Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Apr 9, 2018

Tom De Potter (OLV Hospital, Aalst) discusses the aims of recent trials on ultra-low-temperature continuous ablation and summarises the results, which showed that the system is highly efficacious in an acute setting. Although long-term outcomes are yet to be determined, the results so far show promise in terms of meeting the ultimate goal of achieving electrical block, with 95% acute isolation rates in the first-in-human setting. In terms of safety, Dr De Potter explains, the findings from the studies were also excellent.

Filmed at EHRA 2018, Barcelona.

View more content here: www.touchcardio.com

1. What are that advantages of ultra-low-temperature continuous ablation compared with other ablation approaches? 0:07
2. Please summarise the top-line efficacy data from the first-in-human study of ultra-low-temperature continuous ablation for the treatment of paroxysmal and persistent atrial fibrillation and atrial flutter? 1:03
3. Please describe the top-line safety findings from the first-in-human study of ultra-low-temperature continuous ablation for the treatment of paroxysmal and persistent atrial fibrillation and atrial flutter. 1:54

Loading...

When autoplay is enabled, a suggested video will automatically play next.

Up next


to add this to Watch Later

Add to

Loading playlists...